Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in...
Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall...
View ArticleInvestigational Drug Delays Progression of Non-Small Cell Lung Cancer
The investigational drug PF299804 (PF-299) improves progression-free survival compared with Tarceva® (erlotinib) among patients with advanced non-small cell lung cancer (NSCLC) that has progressed...
View ArticleElderly, Minorities and Women Under-represented in Lung Cancer Clinical Trials
Compared with the demographics of lung cancer in the United States, the elderly, minorities, and women remain vastly under-represented in lung cancer clinical trials. These results were presented at...
View ArticleDrugs That Normalize Gene Expression Show Promise in Lung Cancer
A combination of two drugs—Vidaza® (azacitidine) and the investigational drug entinostat—has shown promise in the treatment of some patients with advanced, previously treated, non-small cell lung...
View ArticlePD-1 Targeted Immune Therapy Shows Promising Activity
The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a...
View ArticleTwo Studies Show Promise in Second-Line Treatments for NSCLC
Two studies presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois shed new light on the best way to treat non-small cell lung cancer (NSCLC)—one...
View ArticleGenetic Study Identifies New Targets for Treating Squamous Cell Lung Cancer
Researchers have identified a large variety of genetic alterations that appear to be responsible for the development and growth of squamous cell lung cancer, according to the results of a study...
View ArticleXalkori Superior to Standard Chemotherapy in ALK-Positive Lung Cancer
The targeted therapy Xalkori® (crizotinib) is superior to standard chemotherapy for the treatment of patients with advanced, ALK-positive non-small cell lung cancer, according to the results of a phase...
View ArticlePatients with Advanced Cancer May Have Inaccurate Expectations of Chemotherapy
Patients with advanced, incurable cancer may have the inaccurate belief that chemotherapy can cure their cancer, according to the results of a study published in the New England Journal of Medicine—and...
View ArticleXgeva Improves Survival Over Zometa in Advanced Lung Cancer
Patients with advanced lung cancer experienced modest improvement in survival when they received bone-targeted therapy with Xgeva® (denosumab) instead of Zometa® (zoledronic acid), according to the...
View ArticleGilotrif Approved for Metastatic EGFR-Positive NSCLC
The U.S. Food and Drug Administration (FDA) has approved Gilotrif™ (afatinib) for the treatment of metastatic non-small cell lung tumors that express specific types of epidermal growth factor receptor...
View ArticleClik here to view.
National Lung Cancer Awareness Month on CancerConnect
November 14, 2014 Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of lung cancer programs for national lung cancer awareness month. As the month of November brings...
View ArticleNovel ALK-Inhibitor Active in NSCLC with Brain Metastasis
The novel targeted agent AP26113 shows strong anti-tumor activity in Xalkori® (crizotinib)-resistant and Xalkori-naïve patients with non-small cell lung cancer, including those with brain metastasis...
View ArticleNintedanib Plus Docetaxel is Effective Second-Line Therapy for NSCLC
Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced non-small cell lung cancer previously treated with one line of platinum-based therapy, according...
View ArticleCeritinib Highly Active in Advanced ALK-Positive NSCLC
The investigational compound ceritinib (LDK378) was highly active in patients with advanced ALK-positive non-small cell lung cancer, according to the results of a study published in the New England...
View ArticleStudy Using Comprehensive Genomic Tumor Testing to Match Lung Cancer Patients...
Data Supports Routine Tumor Genotyping for Patients with Advanced Lung Cancers; May Improve Survival New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for...
View ArticleCyramza With Taxotere Offers Modest Increase in Overall Survival in NSCLC
A phase III randomized trial has shown that Cyramza™ (ramucirumab) combined with Taxotere® (docetaxel) extended overall survival 1.4 months in patients with non-small cell lung cancer (NSCLC) when...
View ArticlePembrolizumab Appears Promising in Treatment of Non-Small Cell Lung Cancer
Results from an ongoing Phase Ib study indicate that treatment with the experimental anti-PD-1 antibody pembrolizumab resulted in high response rates and slowed cancer progression in previously...
View ArticleGilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients...
Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR...
View ArticleInterim Results of X-396 in ALK positive Non-Small Cell Lung Cancer Appear...
Preliminary results from a small phase 1 study of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor showed that X-396 is well tolerated and has antitumor activity in patients with ALK positive...
View Article
